Cargando…

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer

Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warmoes, Marc, Lam, Siu W., van der Groep, Petra, Jaspers, Janneke E., Smolders, Yvonne H.C.M., de Boer, Leon, Pham, Thang V., Piersma, Sander R., Rottenberg, Sven, Boven, Epie, Jonkers, Jos, van Diest, Paul J., Jimenez, Connie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325383/ https://www.ncbi.nlm.nih.gov/pubmed/27566577 http://dx.doi.org/10.18632/oncotarget.11535

Ejemplares similares

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers
por: van der Groep, Petra, et al.
Publicado: (2013)

Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls
por: van Voss, Marise R Heerma, et al.
Publicado: (2010)

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers
por: Vos, Shoko, et al.
Publicado: (2015)

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate
por: Rolfs, Frank, et al.
Publicado: (2021)

Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer
por: Heerma van Voss, Marise R., et al.
Publicado: (2011)

EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
por: Zander, Serge A. L., et al.
Publicado: (2012)

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression
por: Rottenberg, Sven, et al.
Publicado: (2012)

Whole gel processing procedure for GeLC-MS/MS based proteomics
por: Piersma, Sander R, et al.
Publicado: (2013)

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids
por: Paes Dias, Mariana, et al.
Publicado: (2022)

Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals
por: Erozenci, Leyla A., et al.
Publicado: (2021)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice
por: de Groot, Jolien S., et al.
Publicado: (2017)

Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method
por: Bijnsdorp, Irene V., et al.
Publicado: (2017)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Proteomic Profiling of Mycobacterium tuberculosis Identifies Nutrient-starvation-responsive Toxin–antitoxin Systems
por: Albrethsen, Jakob, et al.
Publicado: (2013)

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers
por: Holstege, Henne, et al.
Publicado: (2010)

Pathology of hereditary breast cancer
por: van der Groep, Petra, et al.
Publicado: (2011)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
por: Barazas, Marco, et al.
Publicado: (2018)

Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast
por: Kuijper, Arno, et al.
Publicado: (2005)

Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1α expression
por: Hyseni, Agon, et al.
Publicado: (2011)

Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles
por: Steenbeek, Sander C, et al.
Publicado: (2018)

Secreted protein markers in oral squamous cell carcinoma (OSCC)
por: Mumtaz, Madiha, et al.
Publicado: (2022)

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres
por: Badie, Sophie, et al.
Publicado: (2015)

Preclinical mouse models for BRCA1-associated breast cancer
por: Drost, R M, et al.
Publicado: (2009)

Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells
por: Chaudhuri, Arnab Ray, et al.
Publicado: (2016)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Neutrophil degranulation interconnects over-represented biological processes in atrial fibrillation
por: Kawasaki, Makiri, et al.
Publicado: (2021)

Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture
por: Rajcevic, Uros, et al.
Publicado: (2014)

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum
por: Paciotti, Silvia, et al.
Publicado: (2023)

Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer
por: Böttger, Franziska, et al.
Publicado: (2019)

Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes
por: Kruger, Dinja T., et al.
Publicado: (2020)

Monitoring of Tumor Response to Cisplatin Using Optical Spectroscopy
por: Spliethoff, Jarich W., et al.
Publicado: (2014)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
por: Tacconi, Eliana MC, et al.
Publicado: (2017)

Targeted therapies in renal cell cancer: recent developments in imaging
por: van der Veldt, Astrid A. M., et al.
Publicado: (2010)

Re-assessment of the high-grade serous ovarian cancer phosphoproteome – Identification of kinase candidates in TCGA tumors for future clinical intervention
por: Rolfs, Frank, et al.
Publicado: (2019)

Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0s52ve6ufq594b1e7nqi1sufcl